title: Donepezil 23 mg: An empty suit.
abstract: Donepezil 10 mg/day has been a modestly successful therapeutic agent for the palliative treatment of Alzheimer disease dementia. In 2011, seeking greater efficacy and an extension of the Aricept brand, a 23-mg formulation of donepezil was introduced. A large-scale trial, organized by Eisai, the sponsor, failed to show superiority in their primary analyses of donepezil 23 mg/day in patients with moderate to severe Alzheimer disease dementia vs 10 mg, but the published report used post hoc analyses to claim "statistically significant benefits." There was greater than a 3 times higher rate of gastrointestinal side effects with 23 mg of donepezil compared to 10 mg. Thus, not only does donepezil 23 mg/day increase the likelihood of unacceptable gastrointestinal side effects, it provides no clinical benefits. Aricept 23 mg is about 10 times more costly per pill than donepezil 10 mg.
authors: Alzheimer's Disease Research Center, Department of Neurology, Mayo Clinic, Rochester MN.
authors: David S
authors: DS
authors: Knopman
references: Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S51-6
references: 9236953
references: Neurology. 2001 Aug 14;57(3):481-8
references: 11502917
references: N Engl J Med. 2003 Apr 3;348(14):1333-41
references: 12672860
references: Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22-32
references: 9236949
references: JAMA. 2004 Jan 21;291(3):317-24
references: 14734594
references: Clin Ther. 2010 Jul;32(7):1234-51
references: 20678673
references: N Engl J Med. 2007 Nov 22;357(21):2189-94
references: 18032770
references: Lancet. 1976 Dec 25;2(8000):1403
references: 63862
references: N Engl J Med. 2012 Mar 8;366(10):893-903
references: 22397651
references: Neurology. 1998 Jan;50(1):136-45
references: 9443470